Key result
This review discusses the available experimental and clinical evidence regarding the role of myocardial apoptosis in the progression of pressure-overload cardiomyopathy.
This review summarizes experimental and clinical evidence regarding the role of myocardial apoptosis in the maladaptive transition from compensated hypertrophy to heart failure in pressure-overload cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Extends evidence on apoptosis in pressure-overload cardiomyopathy; leaves open its viability as a therapeutic target.
In the natural history of pressure overload, the hypertrophy response of the left ventricle initially normalizes wall stress and allows preservation of a normal ejection fraction. Nevertheless, patients progress gradually or suddenly from compensated hypertrophy to ventricular dilation with heart failure. Long-standing hypertrophy entails a maladaptive response, which is due to derangements inherent in the myocardium rather than to a progressive increase in the cause of pressure overload. Despite this condition being linked to major clinical consequences and an unfavourable prognosis, the cellular and molecular mechanisms in pressure-overload cardiomyopathy have not yet been established. This review discusses the available experimental and clinical evidence with respect to the role played by myocardial apoptosis in pressure-overload cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Anselmi et al. (2008) conducted a review in Pressure-overload cardiomyopathy. Myocardial apoptosis was evaluated. This review discusses the available experimental and clinical evidence regarding the role of myocardial apoptosis in the progression of pressure-overload cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: